Previous 10 | Next 10 |
Exicure, Inc. (NASDAQ: XCUR) , a pioneer in gene regulatory and immunotherapeutic drugs utilizing spherical nucleic acid (SNA™) technology, will host a virtual R&D Day on Thursday, January 7, 2021 from 09:00 am to 10:30 am ET to discuss Exicure’s neuroscience pipel...
Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Check out Saturday morning's regular Stocks to Watch article for a full list of events planned for the week or the Seeking Alpha earnings calendar for companies due to report. Mond...
Exicure, Inc. (Nasdaq: XCUR), a pioneer in gene regulatory and immunotherapeutic drugs utilizing spherical nucleic acid (SNA™) constructs, today announced that David Giljohann, CEO, will present at the HC Wainwright Virtual BIOCONNECT Conference, January 11-14, 2021. The pres...
Exicure, Inc. (NASDAQ: XCUR) , the pioneer in gene regulatory and immunotherapeutic drugs utilizing spherical nucleic acid (SNA™) technology, announced that it will host a virtual R&D Day on Thursday, January 7 th , 2021 from 09:00 am to 10:30 am ET to discuss Exicure...
Exicure ([[XCUR]] +2.3%) announced that the U.S. Patent and Trademark Office has issued two new patents, No.10,792,251 and No. 10,837,018, and allowed U.S. patent application 14/907,430. This strengthens the Company’s intellectual property position and coverage for the Company’s...
Patents and patent application provide additional coverage for company’s therapeutic for patients with advanced solid tumors Exicure, Inc. (Nasdaq: XCUR), a pioneer in gene regulatory and immunotherapeutic drugs utilizing spherical nucleic acid (SNA™) construct...
EyeGate Pharmaceuticals (EYEG) +87% as it acquires Panoptes Pharma.NantKwest (NK) +32% as its partner, ImmunityBio, achieves primary endpoint in bladder cancer study.RealPage (RP) +31% as Thoma Bravo has agreed to buy the company for $9.6B.China Customer Relations Centers (CCRC...
The following slide deck was published by Exicure, Inc. in conjunction with this event. For further details see: Exicure (XCUR) Investor Presentation - Slideshow
Exicure, Inc. (Nasdaq: XCUR), a pioneer in gene regulatory and immunotherapeutic drugs utilizing spherical nucleic acid (SNA™) constructs, today announced participation in the following conferences during the month of November: 2020 Virtual Guggenheim Healthcare Talks | Ide...
NEW YORK, NY / ACCESSWIRE / November 12, 2020 / Exicure, Inc. (NYSE American:XCUR), is developing nucleic acid-based therapeutics to treat rare, severe genetic diseases and cancer. XCUR will be presenting at this year's virtual Fall Investor Summit on November 16 th -18 th . The Fall Invest...
News, Short Squeeze, Breakout and More Instantly...
Trending Stock
-3.60% Change Percent:
Exicure Inc. Company Name:
XCUR Stock Symbol:
OTCMKTS Market:
Exicure Inc. Website:
A look at the top 10 most actives in the United States Agape ATP Corporation (ATPC) rose 112.1% to $0.3033 on volume of 62,336,784 shares Warrantee Inc. (WRNT) rose 27.8% to $0.372 on volume of 55,635,565 shares Adial Pharmaceuticals Inc (ADIL) rose 110.3% to $2.2295 on volume of 54,549,4...
A look at the top 10 most actives in the United States Serve Robotics Inc. (SERV) rose 187.1% to $7.55 on volume of 255,453,115 shares 60 Degrees Pharmaceuticals Inc. (SXTP) rose 10.2% to $0.271 on volume of 224,640,171 shares NVIDIA Corporation (NVDA) fell 2.6% to $117.93 on volume of 21...
Exicure, Inc. (Nasdaq: XCUR, the “Company”), has historically been an early-stage biotechnology company focused on developing nucleic acid therapies targeting ribonucleic acid against validated targets. In September 2022, the Company announced a significant reduction in force, suspe...